Conclusion
The etiology of Peyronie’s disease has not been fully elucidated, but the inflammatory process has an important place in the disease’s physiopathology. The fact that the only drug that is licensed for the acute phase of the disease is collagenase clostridium histolyticum, and that the effectiveness of other previously-attempted methods has not been fully proven, makes us predict that new treatment modalities will be investigated in the future as well. Our study shows that intralesional usage of low dose methylprednisolone is effective for improving symptoms and signs during the active period of Peyronie’s disease. Thus, it may lead to a more progressive transition of the disease from the acute phase to the chronic phase, resulting in less penile deformity and less subsequent complicated correctional surgeries for affected patients.